RNA-Modifying Enzyme Inhibitors as Synthetic Lethal Cancer Therapeutics
Time: 4:30 pm
day: Day One
Details:
- Expanding the potential impact of helicase inhibitors beyond MSI-H cancers with DHX9-targeted therapeutics
- Validation and drug discovery enablement of RNA modifying nuclease target XRN1 in tumors with elevated interferon signaling
